Uncovering more options in cancer immunotherapy

If scientists want to boost immune cells’ ability to kill cancer cells, then vast libraries of small molecules are potentially available. A new paper shows a platform to sort through them, plus validation. One of the hits: IAP antagonist birinapant, which is already in clinical trials (coincidentally).

Leave a Reply

Your email address will not be published.